Professor Ninian Lang

Professor (Cardiovascular & Metabolic Health)

telephone: 0141 201 1100
email: Ninian.Lang@glasgow.ac.uk

Biography

Ninian Lang is Professor of Cardiology and Cardio-Oncology. He serves as an Honorary Consultant Cardiologist at the Queen Elizabeth University Hospital and the Beatson West of Scotland Cancer Centre. His clinical and academic work focuses on cardio-oncology and heart failure.

He runs the West of Scotland cardio-oncology service and integrates this clinical practice with an active research programme. His clinical trial and translational research in cardio-oncology relates to vascular and myocardial injury induced by established and novel anti-cancer therapies.

He is a graduate of the University of Edinburgh Medical School (BSc [Neuroscience], 1st class Hons, 1998; MBChB 2001, Annandale Gold Medal in Clinical Surgery). He undertook the majority of his clinical training in cardiology in Lothian. He was awarded the Bristol-Myers Squibb Cardiovascular Prize Fellowship to undertake his PhD research (University of Edinburgh; awarded 2009). He was subsequently appointed as Lecturer in Cardiology at the University of Edinburgh, followed by a fellowship in advanced heart failure and cardiac devices at the Scottish Advanced Heart Failure Service. He was appointed as a consultant cardiologist in 2014 before moving to a substantive position with the University of Glasgow. He is a Fellow of the Royal College of Physicians (Edinburgh) and of the European Society of Cardiology. He is an Associate Editor of the JACC:CardioOncology.

Research interests

Research Theme: Cardiac Diseases

Cardiovascular Oncology

Heart Failure

Research groups

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | 2004

Number of items: 115.

2024

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural & inflammatory assessments in non-human primates and lymphoma patients. Clinical Science, (doi: 10.1042/CS20241529) (Accepted for Publication)

Carberry, J. et al. (2024) Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). European Journal of Heart Failure, (doi: 10.1002/ejhf.3560) (Early Online Publication)

Bonaca, M. P. et al. (2024) Cardiovascular safety in oncology clinical trials: JACC: CardioOncology Primer. JACC: CardioOncology, (doi: 10.1016/j.jaccao.2024.09.014) (In Press)

Leong, D. P. et al. (2024) Cardiovascular considerations during cancer therapy: Gaps in evidence and JACC: CardioOncology expert panel recommendations. JACC: CardioOncology, (doi: 10.1016/j.jaccao.2024.06.005) (In Press)

Foley, P.W. et al. (2024) Effect of correcting iron deficiency on the risk of serious infection in heart failure insights from the IRONMAN trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3504) (PMID:39453738) (Early Online Publication)

Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)

Elyan, B. M.P. , Sullivan, M. K. , Hedley, J., De La Mata, N., Webster, A. C., Venugopal, B., Jones, R. J. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2, 57. (doi: 10.1038/s44276-024-00081-7)

Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Shead, K. D., Huethorst, E. , Burton, F., Lang, N. , Myles, R. C. and Smith, G. L. (2024) Human induced pluripotent stem cell derived cardiomyocytes for pre-clinical cardiotoxicity screening. JACC: CardioOncology, (Accepted for Publication)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Curtain, J. P. et al. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, 26(6), pp. 1383-1392. (doi: 10.1002/ejhf.3290) (PMID:38741283)

Rankin, S., Elyan, B. , Jones, R. , Venugopal, B., Mark, P. B. , Lees, J. S. , Petrie, M. C. and Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010) (PMID:38774021) (PMCID:PMC11103039)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)

Sidik, N. P. et al. (2024) Invasive endotyping in patients with angina and no obstructive coronary artery disease: a randomized controlled trial. Circulation, 149(1), pp. 7-23. (doi: 10.1161/CIRCULATIONAHA.123.064751) (PMID:37795617)

2023

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Elyan, B. M.P. , Rankin, S., Jones, R., Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)

Lees, J. S. , Dobbin, S. J.H. , Elyan, B. M.P. , Gilmour, D. F., Tomlinson, L. P., Lang, N. N. and Mark, P. B. (2023) A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation, 38(7), pp. 1666-1681. (doi: 10.1093/ndt/gfac305) (PMID:36318455) (PMCID:PMC10310520)

Henriksen, P. A., Rankin, S. and Lang, N. N. (2023) Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology, 5(3), pp. 292-297. (doi: 10.1016/j.jaccao.2023.05.004) (PMID:37397086) (PMCID:PMC10308056)

Lees, J. S. , Elyan, B. M.P., Hermann, S. M., Lang, N. N. , Jones, R. J. and Mark, P. B. (2023) The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrology Dialysis Transplantation, 38(5), pp. 1071-1079. (doi: 10.1093/ndt/gfac011) (PMID:35090037) (PMCID:PMC10157781)

Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)

Dobbin, S. J.H. , Shen, L., Petrie, M. C. , Packer, M., Solomon, S. D., McMurray, J. J.V. , Lang, N. N. and Jhund, P. S. (2023) Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 25(4), pp. 488-496. (doi: 10.1002/ejhf.2818) (PMID:36919816)

Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)

Cohen, J. B., Brown, N. J., Brown, S.-A., Dent, S., van Dorst, D. C.H., Herrmann, S. M., Lang, N. N. , Oudit, G. Y. and Touyz, R. M. (2023) Cancer therapy–related hypertension: a scientific statement from the American Heart Association. Hypertension, 80(3), e46-e57. (doi: 10.1161/HYP.0000000000000224) (PMID:36621810)

Mayne, K. J., Lees, J. S. , Rutherford, E., Thomson, P. C., Traynor, J. P., Dey, V. , Lang, N. N. and Mark, P. B. (2023) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal, 16(3), pp. 512-520. (doi: 10.1093/ckj/sfac248) (PMID:36865003) (PMCID:PMC9972818)

Lim, M. W.S., Setjiadi, D., Dobbin, S. J.H., Lang, N. N. , Delles, C. and Connelly, P. J. (2023) Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review. Blood Pressure Monitoring, 28(1), pp. 24-32. (doi: 10.1097/MBP.0000000000000624) (PMID:36281701) (PMCID:PMC9815820)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

2022

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

McGettrick, M., Dormand, H., Brewis, M., Johnson, M. K., Lang, N. N. and Church, A. C. (2022) Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular disease. Frontiers in Cardiovascular Medicine, 9, 1004169. (doi: 10.3389/fcvm.2022.1004169) (PMID:36582741) (PMCID:PMC9793745)

de Wit, S., Glen, C., de Boer, R. A. and Lang, N. N. (2022) Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovascular Research, 118(8), pp. 3451-3466. (doi: 10.1093/cvr/cvac132) (PMID:36004495) (PMCID:PMC9897696)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Mark, P. B. , Mangion, K., Rankin, A. J. , Rutherford, E., Lang, N. N. , Petrie, M. C. , Stoumpos, S. and Patel, R. K. (2022) Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. Clinical Kidney Journal, 15(12), pp. 2186-2199. (doi: 10.1093/ckj/sfac146) (PMID:36381379) (PMCID:PMC9664574)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Mangion, K. et al. (2022) Multi-system investigation of COVID-19 illness. British Cardiovascular Society Annual Conference, ‘100 years of Cardiology’, Manchester, UK, 06-08 June 2022. A122.1-A122. (doi: 10.1136/heartjnl-2022-BCS.157)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Dobbin, S. J.H. , Herrmann, S. M.S., Lang, N. N. , Herrmann, J. and Touyz, R. M. (2022) Hypertension and renal disease before anti-cancer therapies. In: Herrmann, J. (ed.) Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease. Elsevier: Philadelphia, PA, pp. 111-122. ISBN 9780323681353 (doi: 10.1016/B978-0-323-68135-3.00020-9)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

Herrmann, S. M.S., Dobbin, S. J.H. , Herrmann, J., Touyz, R. M. and Lang, N. N. (2022) Hypertension and renal disease during anti-cancer therapies. In: Herrmann, J. (ed.) Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease. Elsevier: Philadelphia, PA, pp. 185-199. ISBN 9780323681353 (doi: 10.1016/B978-0-323-68135-3.00029-5)

Lang, N. N. , Dobbin, S. J.H. , Herrmann, S. M.S., Herrmann, J. and Touyz, R. M. (2022) Hypertension and renal failure prevention and management after cancer therapy. In: Herrmann, J. (ed.) Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease. Elsevier: Philadelphia, PA, pp. 286-291. ISBN 9780323681353 (doi: 10.1016/B978-0-323-68135-3.00041-6)

Herrmann, J. et al. (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 43(4), pp. 280-299. (doi: 10.1093/eurheartj/ehab674) (PMID:34904661) (PMCID:PMC8803367)

2021

Lang, N. N. and Touyz, R. M. (2021) Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. Clinical Science, 135(23), pp. 2661-2663. (doi: 10.1042/CS20210986) (PMID:34881389) (PMCID:PMC8672202)

Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)

Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)

Lees, J. S. et al. (2021) Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study. EClinicalMedicine, 38, 101030. (doi: 10.1016/j.eclinm.2021.101030) (PMID:34505030)

Lang, N. N. et al. (2021) Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 23(7), pp. 1147-1155. (doi: 10.1002/ejhf.2138) (PMID:33620131)

Noh, R. M., Graveling, A. J., Lang, N. N. , White, A. C., Lee, K. K., Mills, N. L., Newby, D. E., Lang, C. C. and Frier, B. M. (2021) Effect of hypoglycaemia on measures of myocardial blood flow and myocardial injury in adults with and without type 1 diabetes: a prospective, randomised, open-label, blinded endpoint, cross-over study. Endocrinology, Diabetes and Metabolism, 4(3), e00258. (doi: 10.1002/edm2.258)

Mooney, L., Goodyear, C. S. , Chandra, T., Kirschner, K. , Copland, M. , Petrie, M. C. and Lang, N. N. (2021) Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 135(7), pp. 991-1007. (doi: 10.1042/CS20200306) (PMID:33861346) (PMCID:PMC8055963)

van Dorst, D. C.H., Dobbin, S. J.H. , Neves, K. B. , Herrmann, J., Herrmann, S. M., Versmissen, J., Mathijssen, R. H.J., Danser, A.H. J. and Lang, N. N. (2021) Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circulation Research, 128(7), pp. 1040-1061. (doi: 10.1161/CIRCRESAHA.121.318051) (PMID:33793337) (PMCID:PMC8011349)

Cameron, A. C., Neves, K. B. , White, J., Touyz, R. M. and Lang, N. N. (2021) Reply: Cisplatin-associated aortic thrombosis: a review of cases reported to the FDA adverse event reporting system. JACC: CardioOncology, 3(1), p. 166. (doi: 10.1016/j.jaccao.2021.01.005)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Petrie, M. C. , Lee, M. M. and Lang, N. N. (2021) EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 42(6), pp. 711-714. (doi: 10.1093/eurheartj/ehaa965) (PMID:33367572)

Felker, G. M. et al. (2021) Effects of a novel nitroxyl donor in acute heart failure: the STAND-UP AHF Study. JACC: Heart Failure, 9(2), pp. 146-157. (doi: 10.1016/j.jchf.2020.10.012) (PMID:33248986)

Dobbin, S. J.H. , Petrie, M. C. , Myles, R. C. , Touyz, R. M. and Lang, N. N. (2021) Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 135(1), pp. 71-100. (doi: 10.1042/CS20200305) (PMID:33404052) (PMCID:PMC7812690)

McGettrick, M., MacLellan, A., McCaughey, P., Bagot, C., Brewis, M.J., Lang, N.N. , Johnson, M.K. and Church, A.C. (2021) Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland. BMJ Open, 11, e050281. (doi: 10.1136/bmjopen-2021-050281) (PMID:34462282)

2020

Rossitto, G. et al. (2020) Reduced lymphatic reserve in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 76(24), pp. 2817-2829. (doi: 10.1016/j.jacc.2020.10.022) (PMID:33303070) (PMCID:PMC7724570)

Mangion, K. et al. (2020) The Chief Scientist Office cardiovascular and pulmonary imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 116(14), pp. 2185-2196. (doi: 10.1093/cvr/cvaa209) (PMID:32702087) (PMCID:PMC7454350)

Lang, N. N. , Dobbin, S. J.H. and Petrie, M. C. (2020) Vericiguat in worsening heart failure – agonising over, or celebrating, agonism. Cardiovascular Research, 116(12), e152-e155. (doi: 10.1093/cvr/cvaa247) (PMID:32980877)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Tzolos, E. et al. (2020) Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. Clinical Oncology, 32(5), pp. 292-297. (doi: 10.1016/j.clon.2019.11.008) (PMID:31813662) (PMCID:PMC7139216)

Cameron, A. C., Welsh, P. , Neves, K. B. , Newby, D., Touyz, R. M. and Lang, N. (2020) Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. Journal of Hypertension, 38(2), pp. 257-265. (doi: 10.1097/HJH.0000000000002230) (PMID:31449168) (PMCID:PMC7197298)

2019

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Touyz, R. M. and Lang, N. N. (2019) Hypertension and antiangiogenesis: the Janus face of VEGF inhibitors. JACC: CardioOncology, 1(1), pp. 37-40. (doi: 10.1016/j.jaccao.2019.08.010)

Ahmad, F. A., Petrie, M. C. , McMurray, J. J.V. and Lang, N. N. (2019) Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 21(6), pp. 699-702. (doi: 10.1002/ejhf.1463) (PMID:30972879) (PMCID:PMC6618029)

Cameron, A. C., Rossitto, G., Lang, N. N. and Touyz, R. M. (2019) Antihypertensive drugs and vascular health. In: Zimlichman, R., Julius, S. and Mancia, G. (eds.) Prehypertension and Cardiometabolic Syndrome. Series: Updates in hypertension and cardiovascular protection. Springer, pp. 585-605. ISBN 9783319753096 (doi: 10.1007/978-3-319-75310-2_37)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2019) Vascular biology of cancer chemotherapeutic drugs. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 259-268. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_24)

2018

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Lang, N. N. and Walker, N. L. (2018) Adult congenital heart disease and radiation exposure: the malignant price of cardiac care. Circulation, 137(13), pp. 1346-1348. (doi: 10.1161/CIRCULATIONAHA.117.032815) (PMID:29581364)

2017

Noh, R. M., Venkatasubramanian, S., Daga, S., Langrish, J., Mills, N. L., Lang, N. N. , Hoffmann, E., Waterhouse, B., Newby, D. E. and Frier, B. M. (2017) Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus. Open Heart, 4(2), e000647. (doi: 10.1136/openhrt-2017-000647) (PMID:28912956) (PMCID:PMC5588958)

Touyz, R. M. , Lang, N. N. , Herrmann, J., van den Meiracker, A. H. and Danser, A.H. J. (2017) Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension, 70(2), pp. 220-226. (doi: 10.1161/HYPERTENSIONAHA.117.08856) (PMID:28630211) (PMCID:PMC5509510)

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2017) Cardiovascular complications from cancer therapy: hypertension-focus on vascular endothelial growth factor inhibitors. In: Herrmann, J. (ed.) Clinical Cardio-oncology. Elesvier: Amsterdam, pp. 185-211. ISBN 9780323442275 (doi: 10.1016/B978-0-323-44227-5.00010-7)

2016

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2016) Drug treatment of hypertension: focus on vascular health. Drugs, 76(16), pp. 1529-1550. (doi: 10.1007/s40265-016-0642-8) (PMID:27667708)

Stirrat, C. G., Venkatasubramanian, S., Pawade, T., Mitchell, A. J., Shah, A. S., Lang, N. N. and Newby, D. E. (2016) Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. British Journal of Clinical Pharmacology, 82(4), pp. 974-982. (doi: 10.1111/bcp.13033) (PMID:27275843) (PMCID:PMC5104489)

Pedersen, C. M. et al. (2016) Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury. British Journal of Clinical Pharmacology, 81(6), pp. 1037-1045. (doi: 10.1111/bcp.12882) (PMID:26750458)

Venkatasubramanian, S. et al. (2016) Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus. Open Heart, 3(1), e000402. (doi: 10.1136/openhrt-2016-000402) (PMID:27239324) (PMCID:PMC4879341)

2015

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2015) Vascular complications of cancer chemotherapy. Canadian Journal of Cardiology, 32(7), pp. 852-862. (doi: 10.1016/j.cjca.2015.12.023) (PMID:26968393) (PMCID:PMC4989034)

2014

Lang, N. N. , Badar, A. A., Pettit, S. J., Templeton, S., Connelly, D. T. and Gardner, R. S. (2014) Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy. Biomarkers in Medicine, 8(6), pp. 797-806. (doi: 10.2217/BMM.13.159) (PMID:25224936)

Dalzell, J. R., Cannon, J. A., Jackson, C. E., Lang, N. N. and Gardner, R. S. (2014) Emerging biomarkers for heart failure: an update. Biomarkers in Medicine, 8(6), pp. 833-840. (doi: 10.2217/bmm.14.51) (PMID:25224939)

Lang, N. N. , Wong, C. M., Dalzell, J. R., Jansz, S., Leslie, S. J. and Gardner, R. S. (2014) The ease of use and reproducibility of the Alere™ Heart Check System: a comparison of patient and healthcare professional measurement of BNP. Biomarkers in Medicine, 8(6), pp. 791-796. (doi: 10.2217/bmm.14.48) (PMID:25224935)

Liu, D., Fernandez, B. O., Hamilton, A., Lang, N. N. , Gallagher, J. M.C., Newby, D. E., Feelisch, M. and Weller, R. B. (2014) UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase. Journal of Investigative Dermatology, 134(7), pp. 1839-1846. (doi: 10.1038/jid.2014.27) (PMID:24445737)

McMinn, J. F., Lang, N. N. , McPhadden, A., Payne, J. R., Petrie, M. C. and Gardner, R. S. (2014) Biomarkers of acute rejection following cardiac transplantation. Biomarkers in Medicine, 8(6), pp. 815-832. (doi: 10.2217/bmm.14.56) (PMID:25224938)

Payne, J. and Lang, N. (2014) Heart failure resistant to standard medical therapy. In: Smith, R., Higgins, M. and Macfie, A. (eds.) Cardiothoracic Critical Care. Series: Oxford specialist handbooks in critical care. Oxford University Press. ISBN 9780199692958 (doi: 10.1093/med/9780199692958.003.0021)

2013

Tsang, H. et al. (2013) Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function. Pulmonary Circulation, 3(3), pp. 675-691. (doi: 10.1086/674440) (PMID:24618552) (PMCID:PMC4070793)

Venkatasubramanian, S. et al. (2013) Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. Journal of the American Heart Association, 2(3), e000042. (doi: 10.1161/JAHA.113.000042) (PMID:23770971) (PMCID:PMC3698759)

Japp, A. G. et al. (2013) Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. Journal of the American Heart Association, 2(1), e006007. (doi: 10.1161/JAHA.112.006007) (PMID:23525448) (PMCID:PMC3603266)

Venkatasubramanian, S., Griffiths, M. E., McLean, S. G., Miller, M. R., Luo, R., Lang, N. N. and Newby, D. E. (2013) Vascular effects of Urocortins 2 and 3 in healthy volunteers. Journal of the American Heart Association, 2(1), e004267. (PMID:23525432) (PMCID:PMC3603262)

Lang, N.N. (2013) Cardiology Symposium 2012 Report held on 15 November at the Royal College of Physicians of Edinburgh. Journal of the Royal College of Physicians of Edinburgh, 43(2), pp. 159-160. (doi: 10.4997/JRCPE.2013.214)

Lang, N.N. and Connelly, D.T. (2013) Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation. Journal of the Royal College of Physicians of Edinburgh, 43(2), pp. 151-158. (doi: 10.4997/JRCPE.2013.213)

2012

Alam, S. R. et al. (2012) Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circulation: Cardiovascular Imaging, 5(5), pp. 559-565. (doi: 10.1161/CIRCIMAGING.112.974907) (PMID:22875883)

Lang, N.N. and Newby, D.E. (2012) Cardiac compression causing fatal acute ST-segment elevation myocardial infarction. QJM: An International Journal of Medicine, 105(9), pp. 883-885. (doi: 10.1093/qjmed/hcr131) (PMID:21804101)

Richards, J. M.J. et al. (2012) In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circulation: Cardiovascular Imaging, 5(4), pp. 509-517. (doi: 10.1161/CIRCIMAGING.112.972596) (PMID:22787016)

Cruden, N. L.M., Lang, N. N. , MacGillivray, T. J., Uren, N. G., Fox, K. A.A. and Newby, D. E. (2012) Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb. Heart and Vessels, 27(2), pp. 179-185. (doi: 10.1007/s00380-011-0124-6) (PMID:21394642)

2011

Lang, N. N. , Guðmundsdóttir, I. J. and Newby, D. E. (2011) Vascular PAR-1: activity and antagonism. Cardiovascular Therapeutics, 29(6), pp. 349-361. (doi: 10.1111/j.1755-5922.2010.00140.x) (PMID:20528879)

2010

Lang, N. and Fox, K. (2010) Current drug therapies used in the secondary prevention of MI. Prescriber, 21(19), pp. 22-45. (doi: 10.1002/psb.675)

Venkatasubramanian, S., Newby, D. E. and Lang, N. N. (2010) Urocortins in heart failure. Biochemical Pharmacology, 80(3), pp. 289-296. (doi: 10.1016/j.bcp.2010.03.032) (PMID:20363214)

2009

Mills, N.L., Tura, O., Padfield, G.J., Millar, C., Lang, N.N. , Stirling, D., Ludlam, C., Turner, M.L., Barclay, G.R. and Newby, D.E. (2009) Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart, 95(24), pp. 2003-2008. (doi: 10.1136/hrt.2008.163162) (PMID:19482845)

2008

Lang, N. N. , Cruden, N. L., Tse, G. H., Bloomfield, P., Ludlam, C. A., Fox, K. A. and Newby, D. E. (2008) Vascular B1 kinin receptors in patients with congestive heart failure. Journal of Cardiovascular Pharmacology, 52(5), pp. 438-444. (doi: 10.1097/FJC.0b013e31818c66cb) (PMID:19033823)

Lang, N. N. , Guðmundsdóttir, I. J., Boon, N. N., Ludlam, C. A., Fox, K. A. and Newby, D. E. (2008) Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers. Journal of the American College of Cardiology, 52(1), pp. 33-39. (doi: 10.1016/j.jacc.2008.04.003) (PMID:18582632)

Guðmundsdóttir, I. J., Lang, N. N. , Boon, N. A., Ludlam, C. A., Webb, D. J., Fox, K. A. and Newby, D. E. (2008) Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. Journal of the American College of Cardiology, 51(18), pp. 1749-1756. (doi: 10.1016/j.jacc.2007.12.047) (PMID:18452780)

Lang, N. and Fox, K. (2008) Current drug therapies for the secondary prevention of MI. Prescriber, 19(1), pp. 14-25. (doi: 10.1002/psb.173)

Lang, N.N. , Myles, R.C., Burton, F.L., Hall, D.P., Chin, Y.Z., Boon, N.A. and Newby, D.E. (2008) The vascular effects of rotigaptide in vivo in man. Biochemical Pharmacology, 76(10), pp. 1194-1200. (doi: 10.1016/j.bcp.2008.08.022)

Lang, N. N. and Newby, D. E. (2008) Investigation of patients with suspected chronic heart failure. In: Kearney, M. (ed.) Chronic Heart Failure. Series: Oxford cardiology library. Oxford University Press: Oxford, pp. 23-34. ISBN 9780199542338 (doi: 10.1093/med/9780199542338.003.0003)

2007

Lang, N. N. , Luksha, L., Newby, D. E. and Kublickiene, K. (2007) Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant women. American Journal of Physiology: Heart and Circulatory Physiology, 292(2), H1026-H1032. (doi: 10.1152/ajpheart.00797.2006) (PMID:17085540)

Lang, N. N. and Newby, D. E. (2007) Emerging thrombotic effects of drug eluting stents. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(2), pp. 261-262. (doi: 10.1161/01.ATV.0000255308.41576.ae) (PMID:17229968)

2005

Lang, N. and Fox, K. (2005) Current drug therapies for the secondary prevention of MI. Prescriber, 16(12), pp. 33-44.

2004

Lang, N. , Davie, R., Whitworth, C., Winney, R. and Hughes, J. (2004) Fatal calcific uraemic arteriolopathy (CUA): a case report and review of the literature. Scottish Medical Journal, 49(3), pp. 108-111. (doi: 10.1177/003693300404900313) (PMID:15462229)

This list was generated on Thu Dec 26 01:22:19 2024 GMT.

Jump to: Articles | Book Sections | Conference or Workshop Item